Literature DB >> 8611705

Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia.

J C Kluin-Nelemans1, M G Kester, J J Melenhorst, J E Landegent, L van de Corput, R Willemze, J H Falkenburg.   

Abstract

Hairy cell leukemia (HCL) is characterized by a severe T-cell-mediated immune deficiency. At the same time, spontaneous T-cell activation is noted when splenic T cells are studied in vivo and in vitro. Therefore, we searched for oligoclonal T-cell populations in the blood and spleens of 25 patients with HCL using a T-cell receptor gamma-polymerase chain reaction (TCR gamma-PCR). Subsequently, in 6 patients, the CDR3 length and conformation from 22 different TCRBV subfamilies were analyzed after PCR amplification of cDNA using TCRBV subfamily-specific primers. T cells from 15 of 25 HCL patients showed clonal excess by the TCR gamma-PCR. In fluorescence-activated cell sorted T-cell subsets, more clonal bands were observed than in the unseparated T cells, with most of these in CD8+ subsets, but also in CD4+, CD3+ gamma/delta+, and a double-negative CD3+ alpha/beta+ subset. In other B-cell malignancies, 6 of 16 samples showed oligoclonal T cells, whereas only 2 of 18 normal spleen and blood samples showed abnormal bands. Analysis of the TCRBV subfamilies disclosed in all 6 HCL patients a markedly abnormal pattern, with many clonal bands in 5 to 15 subfamilies, and absent or abnormal weak patterns in another 1 to 8 subfamilies. In comparison, 6 normal samples (2 spleens and 4 blood samples) showed in only 1 blood donor 1 clonal band. Two patients with active HCL but without infections or treatment were tested several times during the course of the disease and showed a complete identical skewed T-cell repertoire with the same oligoclonal T-cell populations. In conclusion, T cells in the blood and spleen of HCL patients show impressive abnormalities with many oligoclonal T-cell populations and a very restricted and skewed TCRBV repertoire.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611705

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

2.  The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis.

Authors:  L Trentin; C Agostini; M Facco; F Piazza; A Perin; M Siviero; C Gurrieri; S Galvan; F Adami; R Zambello; G Semenzato
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 3.  The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.

Authors:  Jan A Burger; Mariela Sivina; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2011-03-25

4.  Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy.

Authors:  Burkhard J Manfras; Hans Weidenbach; Karl-Heinz Beckh; Peter Kern; Peter Möller; Guido Adler; Thomas Mertens; Bernhard O Boehm
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

Review 5.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

6.  A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection.

Authors:  S L Silins; S M Cross; K G Krauer; D J Moss; C W Schmidt; I S Misko
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

7.  The development of peripheral T-cell lymphoma after successful treatment for diffuse large B-cell lymphoma in a patient with suspected adult onset immunodeficiency: more questions than answers?

Authors:  Mari Frances Kilner; Serena Merante; Alexandr Svec
Journal:  BMJ Case Rep       Date:  2013-12-16

8.  Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report.

Authors:  Gorana Gasljevic; Veronika Kloboves-Prevodnik; Barbara Gazic; Marjeta Vovk
Journal:  Diagn Pathol       Date:  2014-03-12       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.